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Abstract   
Cardiac mitochondrial phospholipid acyl chains 
regulate respiratory enzymatic activity. In several 
diseases, the rodent cardiac phospholipidome is 
extensively rearranged; however, whether specific 
acyl chains impair respiratory enzyme function is 
unknown. One unique remodeling event in the 
myocardium of obese and diabetic rodents is an 
increase in docosahexaenoic acid (DHA) levels. 
Here, we first confirmed that cardiac DHA levels 
are elevated in diabetic humans relative to 
controls. We then used dietary supplementation of 
a Western diet with DHA as a tool to promote 
cardiac acyl chain remodeling and to study its 
influence on respiratory enzyme function. DHA 
extensively remodeled the acyl chains of 
cardiolipin (CL), mono-lyso CL, 
phosphatidylcholine, and 
phosphatidylethanolamine. Moreover, DHA 
lowered enzyme activities of respiratory 
complexes I, IV, V, and I+III. Mechanistically, the 
reduction in enzymatic activities were not driven 
by a dramatic reduction in the abundance of   
supercomplexes. Instead, replacement of 
tetralinoleoyl-CL with tetradocosahexaenoyl-CL 
in biomimetic membranes prevented formation of 
phospholipid domains that regulate enzyme 
activity. Tetradocosahexaenoyl-CL inhibited 
domain organization due to favorable Gibbs free 
energy of phospholipid mixing. Furthermore, in 
vitro substitution of tetralinoleoyl-CL with 
tetradocosahexaenoyl-CL blocked complex-IV 
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binding. Finally, reintroduction of linoleic acid, 
via fusion of phospholipid vesicles to 
mitochondria isolated from DHA-fed mice, 
rescued the major losses in the mitochondrial 
phospholipidome and complexes I, IV, and V 
activities. Altogether, our results show that 
replacing linoleic acid with DHA lowers select 
cardiac enzyme activities by potentially targeting 
domain organization and phospholipid-protein 
binding, which has implications for the ongoing 
debate about polyunsaturated fatty acids and 
cardiac health.  
 
 
 
Introduction 
Mitochondria have a central role in 
cardiac physiology by handling differing 
substrates such as pyruvate and fatty acids to 
produce the ATP needed to maintain homeostasis. 
In a range of metabolic diseases such as obesity, 
type 2 diabetes, heart failure, ischemia-reperfusion 
injury, and diabetic cardiomyopathies, cardiac 
mitochondria are subject to considerable 
dysregulation (1-5). One key impairment with 
cardiac mitochondria is the extensive remodeling 
of phospholipid acyl chains, most notably of the 
unique mitochondrial specific phospholipid, 
cardiolipin (CL)1 (6,7). For example, in diabetic 
cardiomyopathies, CL acyl chains undergo 
modifications that broadly include the depletion of 
the most abundant CL species, (18:2)4, as well as 
an increase in longer polyunsaturated acyl chains 
(8,9). In fact, the remodeling of mitochondrial 
phospholipid acyl chains is not just limited to 
cardiomyopathies, but is also reported with 
various other conditions such as aging, obesity, 
and Barth Syndrome (10,11).   
 The mechanisms by which phospholipid 
acyl chain remodeling promotes mitochondrial 
dysfunction remain unclear. Phospholipid acyl 
                                                
1 Abbreviations: (18:2)4CL (tetralinoleoyl-
cardiolipin), (22:6)4CL (tetradocosahexaenoyl-
cardiolipin) 
Cardiolipin (CL), Docosahexaenoic Acid (DHA), 
Eicosapentaenoic Acid (EPA), Monolyso-
Cardiolipin (MLCL), Phosphatidylcholine (PC), 
Phosphatidylethanolamine (PE), n-3 
Polyunsaturated Fatty Acids (n-3 PUFAs) 
chains, particularly linoleic acid associated with 
CL, bind a multitude of trans-membrane and 
membrane associated enzymes to regulate their 
activity. For instance, CL binds oxidative 
phosphorylation complexes I, III, IV, V, and the 
mobile electron carrier cytochrome c (12-17). 
However, it is unknown how remodeling of CL to 
specific fatty acids influences enzyme function. 
 One unique remodeling event in the 
mitochondrial phospholipidome is an increase in 
the abundance of phospholipid species containing 
the long chain n-3 polyunsaturated fatty acid 
(PUFA) docosahexaenoic acid (DHA, 22:6) 
(6,8,9,18). The elevation of cardiac DHA in 
differing cardiovascular diseases is highly 
paradoxical since this fatty acid is considered 
cardioprotective in animal models with some 
supporting evidence in humans (19,20). A recent 
systematic review on the effects of n-3 PUFA 
supplementation in human subjects suggested that 
long chain n-3 PUFAs can be used for 
ameliorating cardiovascular disease risk factors 
(21). However, not all research supports health 
benefits of DHA.  For instance, a rodent study 
showed that DHA did not improve 
cardiomyopathy induced by a Western diet (22).  
 Here we used dietary intervention as a tool 
to study remodeling of mitochondrial 
phospholipids on respiratory enzyme activity. We 
first confirmed that cardiac DHA levels are  
elevated in human diabetics. We then established 
the metabolic profile of mice consuming Western 
diets in the absence or presence of DHA in 
addition to eicosapentaenoic acid (EPA). Next, the 
effects of experimental diets on the mitochondrial 
phospholipidome were investigated. The focus 
was on phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), and CL since they 
are the most abundant phospholipids in the 
mitochondria by mass at 40%, 30%, and 15-20%, 
respectively (23). We then determined if the 
experimental diets impaired mitochondrial 
respiratory enzyme activities since CL binds 
several of these enzymes (14,16,24-29). 
Mechanistically, we investigated if DHA lowered 
enzyme activities due to modifications in the 
formation of supercomplexes, assembly of lipid 
domains that regulate protein activity, and 
phospholipid-protein binding interactions (30-32). 
Finally, experiments were conducted to determine 
if reintroduction of linoleic acid into mitochondria 
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isolated from mice consuming DHA rescued 
remodeling in the phospholipidome and thereby 
enzymatic function.  
 
Results 
Cardiac DHA levels are elevated in human 
diabetics.  Data from rodent studies demonstrate 
that cardiac DHA levels are elevated in differing 
diseases (9,18); however, evidence in humans in 
lacking. Therefore, cardiac DHA levels from non-
diabetic and diabetic subjects were first assayed.  
Mitochondria could not be isolated since there was 
extremely limited tissue samples from surgery. 
Furthermore, fatty acid analyses had to be 
conducted with total extracted fatty acids due to 
the small amount of tissue obtained during 
surgery. Analyses with GC revealed that diabetics, 
relative to non-diabetic controls, had no changes in 
the levels of saturated fatty acids (Fig. 1A). The 
monounsaturated fatty acid 16:1 was lowered by 
2.4 fold with diabetic subjects relative to the non-
diabetics (Fig. 1B).  N-6 PUFA levels were not 
modified (Fig. 1C).  Analyses of the major n-3 
PUFAs showed that DHA levels were increased 
by 1.7 fold for the diabetic subjects compared to 
non-diabetic controls (Fig. 1D).  
 
Mice consuming Western diets in the absence and 
presence of EPA and DHA generally have 
impaired glucose clearance. Subsequent studies 
were conducted with mice. It was first established 
how murine experimental diets influenced fat/lean 
mass, glucose clearance, and fasting insulin levels. 
The effects of EPA and DHA were tested at two 
different time points, including consumption of the 
fatty acids for 14 weeks or for 4 weeks (Fig. 2A). 
Mice fed the Western diet and the EPA or DHA 
enriched Western diets had increased total body 
weights by 1.3-1.4 fold relative to the lean control 
(Fig. 2B). The increase in total body weight was 
accounted for by an increase in fat mass with the 
Western and EPA or DHA enriched Western diets 
by 1.9-2.1 fold relative to the control (Fig. 2C). 
Mice fed the Western+EPA diet (14 and 4 wks) 
and the Western+DHA diet (4 wks) had elevated 
lean mass compared to lean animals (Fig. 2D). 
Mice fed the Western diets in the absence or 
presence of EPA or DHA generally had 
diminished glucose clearance (Fig. 2E), as 
quantified by the area under the curve (AUC) for 
glucose clearance (Fig. 2F). The only exception 
was the Western diet+EPA (4 wks) (Fig. 2F).  
Mice fed the Western diets in the absence and 
presence of EPA (4 wks) or DHA (14 wks and 4 
wks) had increased fasting insulin levels in 
comparison to lean mice (Fig. 2G). The 
Western+DHA diet (14 and 4 wks) increased 
fasting glucose levels compared to the control 
and/or the Western diet (for 14 wks) (Fig. 2H). 
HOMA-IR scores were consistently increased with 
all of the Western diets, except the WD+EPA (14 
wks), relative to lean mice (Fig. 2I). There were no 
statistically significant differences between EPA 
and DHA (14 and 4 wks) for HOMA-IR scores. 
Altogether, the data suggested that 
supplementation with EPA or DHA did not 
improve glucose clearance although long-term 
intake with EPA did not increase the HOMA-IR 
score relative to lean mice, consistent with 
previous work (33). 
  
Murine cardiac mitochondrial CL and monolyso-
CL acyl chains are dramatically remodeled in 
response to Western diets in the absence and 
presence of EPA and DHA. We next established 
how the Western diets, particularly in the presence 
of EPA and DHA, targeted CL and monolyso-CL 
(MLCL) acyl chains. An example of the raw 
LC/MS data are presented in Fig. S1A-D. LC/MS 
analyses are presented as heat maps in Figure 3.  
CL species  were classified as either major (Fig. 
3A), intermediate (Fig. 3B), or minor (Fig. 3C) in 
terms of abundance. MLCL levels are shown in 
Fig. 3D. 
 The most abundant CL species, (18:2)4, 
was robustly reduced with all of the Western diets 
by 4.3-20.0 fold (Fig. 3A, Fig. S2A-F). The 
Western diet, in the absence of EPA (4 and 14 
wks) or DHA (4 and 14 wks), also increased a 
range of other major CL species relative to the 
control and the Western diet (Fig. 3A). CL species 
containing 22:6 were elevated in response to EPA 
intervention and robustly with DHA intervention 
(4 and 14 wks).  The increase in differing CL 
species came at the expense of lowering a range of 
CL species, notably containing 18:2 and 20:4 acyl 
chains (Fig. 3A). Several intermediate and minor 
CL species were also increased or decreased with 
the Western diet, in the absence or presence of 
EPA or DHA, when compared to the control by 
2.0-14.0 fold (Fig. 3B, 3C). There were also some 
differences between EPA and DHA (Fig. S2A-F).  
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Murine cardiac mitochondrial PC and PE acyl 
chains are remodeled in response to a Western 
diet in the absence and presence of EPA and DHA. 
LC/MS analyses were also conducted with PC and 
PE phospholipids. Generally, the Western diet in 
the absence and presence of EPA (14 wks and 4 
wks) and DHA (14 and 4 wks) lowered the 
abundance of PCs containing 16:0, 18:1, 18:2, and 
20:3 acyl chains by 1-2-fold compared to the lean 
controls (Fig. 4A). For some species such as 
(18:2)2PC, the effects were more robust with DHA 
(14 and 4 wks) compared to EPA (14 and 4 wks) 
(Fig 4A). DHA also notably increased the levels of 
(18:2)(20:4)PC compared to control, Western diet, 
and Western diet+EPA fed mice.   Similar trends 
were observed with PEs, where the Western diet in 
the absence or presence of EPA (14 and 4 wks) 
and DHA (14 and 4 wks) lowered species 
containing 16:0, 18:1, and 18:2 acyl chains (Fig. 
4B). DHA had stronger effects than EPA on some 
PEs (Fig. 4B).  
 
Cardiac mitochondrial respiratory enzyme 
activities are decreased with the EPA and DHA 
enriched Western diets. Subsequent experiments 
addressed if the aforementioned changes in the 
mitochondrial phospholipidome were associated 
with impaired respiratory enzyme activities. We 
focused on long-term of intake of EPA and DHA 
(14 wks). Strikingly, mice that consumed the 
Western diet did not have a reduction in enzyme 
activities and combined enzyme activities when 
compared to the lean control (Fig. 5A-G). The 
Western+EPA and Western+DHA diets (14 wks) 
respectively reduced complex I activity by 1.8 and 
1.9 fold relative to the control diet (Fig. 5A). The 
EPA and DHA containing diets had no effect on 
complex II (Fig. 5B) and complex III (Fig. 5C) 
activities.  Complex IV activity was lowered with 
the EPA or DHA enriched Western diets relative 
to the control and/or Western diet by 1.8-2.7 fold 
(Fig. 5D). The Western+DHA diet (14 wks) also 
modestly reduced complex V activity by 0.6 fold 
relative to the control (Fig. 5E). The 
Western+DHA diet decreased the combined 
activities of complex I+III by 2.0 fold compared to 
the control (Fig. 5F). There was no effect of EPA 
and DHA enriched Western diets on complex 
II+III activities (Fig. 5G).   
 
EPA and DHA do not robustly suppress formation 
of the major supercomplexes. The next study 
addressed if decreased enzyme specific activities 
with EPA or DHA (14 wks) were mechanistically 
driven by a reduction in mitochondrial 
supercomplex formation or in the expression 
levels of the complexes (34).  Long-term intake of 
EPA or DHA had no major effect on the majority 
of the supercomplexes, which are depicted as 
supercomplexes 1-5 (Fig. S3A-F) (35). The 
notable exception was that mice consuming the 
Western+DHA diet had a reduction in the amount 
of supercomplex 4 when compared to the control 
and Western diets by 2.5 and 2.7 fold, respectively 
(Fig. S3E). Blue native (BN)-PAGE analysis also 
revealed that there were no changes in complexes 
I, II, III, IV, and V expression in the Western and 
EPA or DHA enriched Western diets compared to 
the lean control (data not shown).  
 
Replacement of (18:2)4CL with (22:6)4CL prevents 
the formation of lipid domains by influencing the 
Gibbs free energy of lipid-lipid mixing. Given that 
DHA did not robustly impair the abundance of the 
majority of supercomplexes, we investigated 
another potential mechanism by which respiratory 
enzyme activity could be lowered with DHA. We 
used a biophysical approach to determine if DHA 
could target the formation of CL domains, which   
control phospholipid-protein binding that is 
critical for optimal enzyme function (36). 
Biomimetic mitochondrial membranes modeling 
the composition of the cardiac inner mitochondrial 
membrane were used since they allow for a 
controlled model system. (22:6)4CL was 
specifically investigated given that it is a 
symmetric phospholipid and was elevated in 
response to DHA in the diet (Fig. 3A, Fig. S2F). 
Cytochrome c was added to the biomimetic 
membranes since it known to induce domain 
formation in giant unilamellar vesicles (37).   
Imaging revealed that (18:2)4CL promoted 
the formation of phase separated domains (as 
visualized by NAO), which were diminished upon 
replacement of (18:2)4CL with (22:6)4CL (Fig. 
6A). A range of phase separated domain areas 
were measured with the NAO fluorescent probe 
and are presented as a frequency distribution. A 
Gaussian fit was applied to the frequency 
distributions with larger areas reflecting greater 
coverage of the NAO fluorophore on the perimeter 
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of the giant unilamellar vesicles (Fig. 6B). Visual 
inspection of the frequency distributions of the 
domains were clearly different between (18:2)4CL 
and (22:6)4CL  (Fig. 6B). Quantification of the 
average area occupied by the NAO probe showed 
that DHA prevented formation of phase separated 
domains (Fig. 6C).    
 To explain how (22:6)4CL prevented 
domain formation, monolayers of the same lipid 
mixtures modeling the inner mitochondrial 
membrane were constructed containing either 
(18:2)4CL (Fig.6D) or (22:6)4CL (Fig. 6E) in the 
absence or presence of cytochrome c. This model 
system allowed us to investigate phospholipid 
mixing properties that are central for the formation 
of phase separated lipid domains (38). The 
monolayer pressure area isotherms (Fig. 6D, 6E) 
were then used to calculate the change in excess 
area per molecule in response to cytochrome c. 
The excess area per molecule values provide a 
quantitative change at the angstrom level on how 
phospholipids are mixing or de-mixing (i.e. lipid-
lipid miscibility) (39).  
In biomimetic mitochondrial monolayers 
containing (18:2)4CL, the change in excess area 
per molecule was positive, indicating unfavorable 
lipid mixing (i.e. formation of phase separated 
domains) (Fig. 6F). Upon replacement of 
(18:2)4CL with (22:6)4CL, this value became 
negative, indicating favorable  mixing between 
phospholipids (i.e. no formation of phase 
separated domains). We further calculated the 
change in Gibbs free energy of mixing upon the 
addition of cytochrome c. (18:2)4CL had a positive 
change in Gibbs free energy of mixing, indicating 
unfavorable mixing of phospholipids (Fig. 6G). 
Replacement of (18:2)4CL with (22:6)4CL shifted 
the Gibbs free energy of mixing to a favorable 
negative value. Thus, these results established that 
(18:2)4CL promoted phase separated domains due 
to unfavorable lipid mixing. In contrast, the lack of 
domains in the presence of (22:6)4CL was driven 
by favorable Gibbs free energy of mixing between 
phospholipids.     
 
Replacement of (18:2)4CL with (22:6)4CL 
diminishes interactions with complex IV. CL 
domains are hypothesized to create a 
microenvironment that regulates protein activity 
through direct phospholipid-protein binding 
(12,15,25,40)  Thus, we further investigated if 
replacement of (18:2)4CL with (22:6)4CL in 
biomimetic mitochondrial large unilamellar 
vesicles (LUVs) impaired binding interactions 
with immobilized complex IV using surface 
plasmon resonance (SPR) (41). Complex IV was 
selected since its activity was lowered with DHA, 
suggesting that  the known high-affinity, CL-
specific binding sites (27,42-44) may be unable to 
accommodate remodeled CL. SPR binding curves 
showed dramatic differences in binding 
interactions between complex IV and LUVs 
containing either (18:2)4CL (Fig. 7A) or (22:6)4CL 
(Fig. 7B). Strikingly, there was a lack of 
detectable LUV-CIV interactions in presence of 
(22:6)4CL at LUV concentrations nearly 100-fold 
higher than the reported apparent Kd for CL 
binding to the high and low affinity sites on CIV 
(< 0.1 µM and 4 µM, respectively) (43). Fitting of 
the binding curves for LUVs containing (18:2)4CL 
relied on a one site binding equation. The fitting 
revealed an equilibrium binding constant (Kd) of 
1.8 ± 0.6 µM (Table 1), consistent with lipid-
protein interactions at CL-specific binding sites.  
 
 (18:2)4CL rescues the major remodeling in the 
cardiolipin lipidome induced by long-term intake 
of DHA.  The last set of experiments tested the 
possibility that the replacement of the predominant 
CL fatty acid, linoleic acid (18:2) with DHA 
(22:6), was driving the reduction in enzyme 
activity. Therefore, we fused cardiac mitochondria 
isolated from mice consuming the Western+DHA 
(14 wks) diet with small unilamellar vesicles 
comprised of (18:2)4CL.  We ensured that 
(18:2)4CL fusion did not influence the fatty acids 
associated with PC or PE. LC/MS heat maps show 
no alterations in any of the acyl chains associated 
with PC (Fig S4A) and PE (Fig. S4B) upon fusion 
with (18:2)4CL. 
CL and MLCL were analyzed in response 
to the fusion. LC/MS analyses are presented as 
heat maps in Figure 8 for CL species that were 
classified as either major (Fig. 8A), intermediate 
(Fig. 8B), or minor (Fig. 8C) in terms of 
abundance. MLCL was also analyzed (Fig. 8D). 
Several intermediate and minor CL species were 
altered in the (18:2)4CL mitochondrial fusion 
when compared to control and Western+DHA 
diets by 1.7-10.0 fold (Fig. 8B, 8C). Notably, the 
most abundant CL species, (18:2)4, was increased 
back to control levels with the fusion of (18:2)4CL 
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by 12.6 fold relative to the Western+DHA (14 
wks) diet (Fig. 8A). In addition, fusion with 
(18:2)4CL increased (18:1)(18:2)3 by 4.3 fold 
relative to the Western+DHA (14 wks) diet (Fig. 
8A). The fusion with (18:2)4CL also decreased 
several other CL species by 3.1-4.7 fold relative to 
the Western+DHA (14 wks) diet (Fig. 8A). 
Relative to the control, fusion with (18:2)4CL still 
displayed decreased levels of some CL species 
such as (18:1)(18:2)3 (Fig. 8A).  
 
Cardiac mitochondrial complex I, IV and V 
activities are rescued upon introduction of 
(18:2)4CL into the mitochondria of mice 
consuming DHA. We determined if improvement 
in the CL lipidome of DHA-fed mice upon fusion 
of (18:2)4CL rescued the impaired oxidative 
phosphorylation enzyme activities.  The fusion of 
(18:2)4CL to control samples had no effect on 
enzyme activity (data not shown). The fusion of 
(18:2)4CL to mitochondria isolated from 
Western+DHA (14 wks) rescued complex I 
activity (Fig. 9A). The fusion of (18:2)4CL with 
the Western+DHA (14 wks) diet did not influence 
complex II activity (Fig. 9B) and complex III 
activity was reduced relative to the control diet by 
2.5 fold (Fig. 9C). (18:2)4CL fusion rescued 
complex IV and complex V activities by 2.4 and 
2.5 fold relative to the Western+DHA diet (Fig. 
9D-E). Complex II and II+III activities were not 
influenced by the introduction of (18:2)4CL (Fig. 
9F, G).  
 
Discussion  
The rationale for the study was based on 
previous data showing rearrangement of cardiac 
mitochondrial phospholipid acyl chains, 
particularly CL, in several diseases like 
cardiomyopathies and diabetes, as well as aging 
(8-11,18).  In such scenarios, decreased 
mitochondrial supercomplex formation, decreased 
mitochondrial respiratory function, increased 
oxidative stress and  elevated cardiac DHA acyl 
chains levels are generally observed (18,45-54).  
Herein, we first confirmed mouse studies 
by demonstrating that DHA levels were elevated 
in human type II diabetics. A limitation of this 
study was that we were not able to assay if DHA 
was specifically associated with the polar lipid 
pool, particularly CL. This was due to a very 
limited tissue sample size obtained during surgery.  
Given that the concentration of free fatty acids is 
significantly low in the heart (55), it is likely that 
DHA levels represent polar and neutral lipids. We 
also acknowledge that the size of the samples, 
which were very difficult to obtain, was small. 
Thus, future studies will need to further confirm if 
DHA levels, particularly in CL, are elevated in 
human subjects while controlling for various 
confounding variables.  
Following the human study, we  
performed experiments in a murine model to 
determine the potential underlying mechanisms by 
which DHA acyl chains influence mitochondrial 
enzymatic activity. A striking finding from the 
mouse study was that the Western diet in the 
absence of EPA or DHA dramatically remodeled 
the lipidome of the three major phospholipids of 
the mitochondria, but had no effect on enzyme 
activity, even upon a strong reduction in (18:2)4CL 
levels. These results were in agreement with our 
previous work that showed a high fat diet had no 
influence on mouse cardiac enzyme activity upon 
moderate remodeling of phospholipids (56). In 
contrast, remodeling of the phospholipidome upon 
dietary supplementation with EPA and DHA led to 
diminished enzymatic activity of select complexes. 
These results were consistent with a study 
showing that fish oil can lower liver mitochondrial 
complex IV and V activities (57).  
 
DHA potentially lowers cardiac mitochondrial 
enzyme activities by influencing domain 
organization and protein-lipid binding. The data 
suggest two potential mechanisms, which are not 
mutually exclusive, by which DHA lowered 
respiratory enzyme function. One possibility was 
that DHA prevented CL domain formation. 
Studies with biomimetic membranes specifically 
showed that (22:6)4CL had a stronger effect than 
(18:2)4CL on domain formation, which was driven 
by the ability of DHA acyl chains to promote 
phospholipid mixing.  The other possibility was 
that DHA prevented binding of linoleic acyl 
chains to specific complexes.  
There are several binding sites within 
complex I and IV that could be influenced by 
DHA. There are 9 binding sites for CL in bovine 
complex I and depletion of CL from complex I 
renders the enzyme inactive (24,25). Similarly, CL 
is required for complex IV activity with 4 known 
CL binding sites of which two are considered high 
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affinity. The high affinity CL binding sites are 
associated with the regulation of electron transport 
and the loss of CL at these sites lowers enzymatic 
activity (26,27). The two low affinity sites are also 
important in the structural integrity of the complex 
in its dimer form (28,58). Thus, DHA acyl chains 
may lower enzyme function due to diminished 
binding of linoleic acid to either of the two 
complexes. Indeed, studies to determine the 
strength of the phospholipid-protein interactions 
with  complex IV revealed that biomimetic 
membranes containing (22:6)4CL did not bind to 
complex IV while those containing (18:2)4CL 
exhibited significant interactions with complex IV 
(presumably both the low and high affinity CL-
binding sites). Disruption of (22:6)4CL binding to 
complex IV could result in reduced 
conformational flexibility or electron transport, 
effectively reducing enzyme activity. Subsequent 
studies will need to test binding of other DHA-
containing CL species with complex IV and other 
complexes. It was beyond the scope of this study 
to test CL binding kinetics with all of the 
complexes.   
Complex V activity was also lowered with 
DHA, which could be due to a specific disruption 
in CL domain formation. Complex V forms dimers 
and CL is specifically needed to assemble the 
enzymes into larger oligomeric structures, which 
effects energy efficiency (16,29,59). It is possible 
that DHA, due to unique conformational 
flexibility, imparted disorder on the bilayer that 
lead to an impairment in the formation of higher 
order complex V oligomers that rely on the 
microdomain environment.  
The effects of DHA on domain 
organization could also explain the reduction in 
complex I+III activity. Perhaps DHA lowered the 
ability of coenzyme q, the mobile electron carrier 
from complex I to complex III, to diffuse 
appropriately as the domains were disrupted. This 
would then explain why modifications to complex 
I and III activity alone did not recapitulate the 
results with complex I to III electron transfer. It is 
also conceivable that DHA impaired other aspects 
of membrane biophysical organization such as 
bending rigidity that could impede electron flow 
(60). 
There are likely additional mechanisms by 
which DHA could lower respiratory enzyme 
function. These would include the possibility that 
an increase in acyl chain unsaturation with dietary 
DHA could manipulate CL turnover and thereby 
protein activity (61). In addition, DHA may have 
indirect effects on enzymatic responses by 
influencing the expression and activity of 
phospholipase A2γ, which cleaves select fatty 
acids from CL to regulate mitochondrial 
bioenergetics (62). 
Despite the clear impact that 
mitochondrial membrane phospholipidome 
remodeling was having on respiratory complex 
activity, it is noteworthy that coupled ADP-
stimulated respiration was not altered with  EPA 
and DHA (data not shown). This effect mirrored 
our previous study where EPA/DHA 
supplementation in high fat-fed mice did not 
significantly alter maximal respiration in the heart 
(63). This fact illustrates the complexity of 
mitochondrial bioenergetics and suggests that 
while discrete respiratory complexes may be 
altered individually, or even in aggregate (i.e. 
supercomplexes), that there are additional factors 
that impinge on respiratory function as a whole 
when mitochondria are intact and fully coupled. 
Altogether, the data provide a roadmap for future 
studies that will require purification of differing 
respiratory enzymes to study how DHA acyl 
chains disrupt enzyme activity in the context of 
CL-protein binding and formation of CL domains.  
 
The paradox on DHA. In conditions such as 
obesity and type 2 diabetes, that are linked to 
cardiovascular diseases, pathological remodeling 
of CL with EPA and/or DHA increases oxidative 
damage that contributes to mitochondrial 
dysfunction (64). For instance, a study showed 
that DHA levels in C2C12 cells were elevated 
upon upregulation of ALCAT1 (a lyso-CL 
acyltransferase), which remodels CL to species 
containing highly oxidizable acyl chains and 
increased oxidative stress (64). A deficiency in 
ALCAT1 in a murine model protected against diet 
induced obesity and insulin resistance (64). 
Shotgun lipidomic studies by Han et. al. also 
showed a significant decrease in CL abundance 
and a profound remodeling of the remaining CL 
species to include DHA acyl chains in rat diabetic 
myocardium (9,18).  
In contrast, many studies demonstrate that 
consumption of EPA/DHA can have beneficial 
effects in obesity and type 2 diabetes through 
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pleiotropic mechanisms. The mechanisms for 
improvements with EPA and DHA consist of 
enhancing insulin signaling, maintaining glucose 
metabolism, reversing dyslipidemia, and resolving 
inflammatory signals via targeting of transcription 
factors and gene expression (65-68). For instance, 
in a similar study by our group, supplementation 
of EPA and DHA in high fat diet led to increased 
levels of 4-hydroxyhexenal (HHE) adducts in the 
myocardium, products of EPA/DHA specific lipid 
peroxidation (63). In parallel with the increase in 
HHE-adducts, antioxidant gene expression 
increased while mitochondrial ROS production 
decreased in the heart, suggesting that high fat diet 
supplementation with EPA/DHA caused a 
beneficial ‘hormetic’ response in the heart. Similar 
effects were also seen to some extent in a recent 
small clinical trial of fish oil in patients prior to 
cardiac surgery. Anderson et al, showed that 
patients consuming 4 g/day of EPA/DHA ethyl 
esters (Lovaza™) had increased myocardial 
PPARγ activation, upregulated fatty acid 
metabolic gene expression, greater 
expression/activity of antioxidant as well as anti-
inflammatory enzymes, and increased palmitoyl-
carnitine supported respiration (69).  
 
The role of linoleic acid in the myocardium. 
Introduction of linoleic acid in CL vesicles 
rescued the decrement in the phospholipidomic 
profile and enzyme activities of complexes I, IV, 
and V in response to DHA. These results 
demonstrate mechanistically that it is not the loss 
of linoleic acid alone that drives the impairment in 
enzyme function since the Western diet alone did 
not impair enzyme activities. Instead, it was the 
replacement of linoleic acid with DHA that 
promoted the reduction in activities. The notable 
exception was complex III activity, which was not 
restored upon introduction of linoleic acid. 
Perhaps DHA was bound to complex III in a 
manner that precluded displacement by linoleic 
acid associated with CL. Several of the known 
complex III CL-specific bindings sites are buried 
deep within protein cavities, presumably making 
displacement of the DHA-containing CL difficult 
due to structural constraints (15).    
The (18:2)4CL rescue data advances the 
field by highlighting the importance of n-6 PUFAs 
in mitochondrial membranes. There is 
considerable debate about the effects of n-6 
PUFAs, notably linoleic acid, on cardiovascular 
health. Initially, linoleic acid was hypothesized to 
have benefits for cardiovascular outcomes since it 
lowers serum cholesterol (70,71). However, recent 
studies challenge this notion about increasing the 
intake of linoleic acid at the expense of saturated 
fatty acids (72). For instance, several meta-
analyses show that increasing the dietary 
consumption of n-6 PUFAs, at the expense of 
saturated fatty acids, does not lower the risk of 
death from cardiovascular diseases (73-75). In 
addition to n-6 PUFAs, the role of n-3 PUFAs in 
cardiovascular diseases is still controversial. Meta-
analyses on the consumption of EPA and DHA 
and coronary heart disease indicate that n-3 
PUFAs may be associated with lowered 
cardiovascular risk (76,77). On the other hand, a 
recent clinical trial showed that daily treatment 
with n-3 PUFAs did not decrease the prevalence of 
cardiovascular mortality or morbidity in patients 
with multiple cardiovascular risk factors (78). Our 
data suggest that linoleic acid is key for cardiac 
mitochondrial enzymatic activity and its 
replacement, at least with select doses of DHA, 
could promote impairments.   
  It is conceivable that EPA and/or DHA 
could improve cardiac enzyme activities in other 
model systems. In this model, we did not find that 
DHA was improving fasting insulin or glucose 
clearance in contrast to other studies (33,79). 
Thus, perhaps DHA could improve enzyme 
activities under conditions in which whole body 
metabolism is improved. Furthermore, DHA in the 
triglyceride or free fatty acid form may have 
different effects on the mitochondrial 
phospholipidome and enzymatic activity, which 
was beyond the scope of this study. 
 
Conclusions. The data demonstrate that 
remodeling of the murine cardiac mitochondrial 
phospholipidome  in the absence of DHA had no 
influence on mitochondrial enzyme activities. In 
contrast, remodeling of the phospholipidome with 
DHA, in particular, lead to a reduction in complex 
I, IV, V, and I+III activities, potentially through 
mechanisms involving the formation of lipid 
domains and phospholipid-protein binding. These 
results suggest that increased levels of DHA in the 
myocardium in differing diseases may be targeting 
enzymatic activity. Furthermore, the impairments 
with DHA in the lipidome were generally rescued 
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with the introduction of linoleic acid accompanied 
by an improvement in the activities of select 
complexes. This has implications for future studies 
on the balance between linoleic acid and n-3 
PUFAs in the heart.  
 
Experimental Procedures 
Human subjects.  The Institutional Review Board 
of East Carolina University approved all aspects of 
human tissue and data collection for this study.  
The cohorts evaluated were type 2 diabetic and 
non-diabetic patients at Vidant Hospital 
undergoing elective coronary artery bypass graft 
surgery. The demographic and clinical data 
pertaining to the patients are shown in Table S1.  
The subjects were grouped either as non-diabetic 
or diabetic according to two major variables: 1) 
clinical diagnosis of diabetes; and 2) glycated 
hemoglobin (HbA1c) values of ≥ 6.1 extending up 
to approximately 1 year prior to surgery.  It is 
standard of care at Vidant Hospital to give all 
diabetic patients intra-venous insulin when 
admitted for surgery and all other pre-operative 
diabetic medications are noted in Table S1.  
Patients with enlarged atria, history of arrhythmia, 
or left ventricular ejection fractions < 30% were 
excluded from this study.  
  
Human atrial appendage biopsy, tissue 
processing, and fatty acid analyses. After median 
sternotomy, and prior to institution of 
cardiopulmonary bypass, a purse-string suture was 
placed in the right atrial appendage to allow for 
placement of the venous cannula.  A sample of the 
appendage directly superior to the purse-string was 
dissected and immediately rinsed in ice-cold saline 
to remove excess blood, trimmed of the epicardial 
layer and pericardial fat, and frozen in liquid N2.  
Total fatty acids from the atrial appendage were 
extracted with organic solvents (HPLC grade, 
Sigma) and analyzed with gas chromatography 
(GC) as previously described (80). Stringent 
precautions were taken to prevent oxidation (80). 
 
Animals and diets. All experiments were 
conducted in accordance with guidelines 
established by the Guide for the Care and Use of 
Laboratory Animals (NIH Publication No. 85–23, 
revised 1996) and with prior approval by the 
Animal Care and Use Committee at East Carolina 
University and at The University of North 
Carolina at Chapel Hill. Male C57BL/6 mice 
(Charles River, Wilmington, MA), 5 weeks old, 
were fed a low fat control diet, a Western diet 
(42% of kcal from milkfat), or a Western diet with 
2% kcal from either EPA or DHA ethyl esters for 
14 weeks (Envigo Inc. Indianapolis, IN). Short-
term intervention with EPA and DHA was also 
tested, which entailed feeding mice the Western 
diet for 10 weeks followed by 4 weeks of the 
Western diet with either EPA or DHA. EPA and 
DHA ethyl esters (Cayman Chemicals, Ann Arbor, 
MI) were greater than 93% purity and were 
routinely tested for oxidation prior to and during 
the course of the study. The composition of the 
experimental diets is presented in Table S2. Mice 
were housed on a 12:12 h light-dark cycle with 
free access to water. Mice were sacrificed via 
isoflurane inhalation followed by cervical 
dislocation. 
 
Metabolic profiling. Mice were fasted for 5 hrs 
prior to the administration of an intraperitoneal 
glucose injection (2.5 g/kg fat-free mass) of a 50% 
dextrose saline solution (Hospira Inc, Lake Forest, 
IL) (81). Blood glucose was monitored from the 
tail vein using an AlphaTrak 2 animal glucometer 
(Abbott Laboratories, Chicago, IL) at 0, 15, 30, 
60, and 90 mins post-injection (82). Values were 
normalized to fasting blood glucose levels and 
glucose tolerance was assessed by calculating the 
corresponding area under the curve (AUC). Blood 
samples, collected after the 5 hr fast using 
microcapillary tubes, were used to quantify insulin 
levels with an Ultra-Sensitive Mouse Insulin 
ELISA Kit (Crystal Chem Inc., Downers Grove, 
IL). Fat and lean masses were determined with 
whole-body EchoMRI (Active Field Resources, 
LLC, Houston, TX). 
 
Isolation of mitochondria. Mitochondrial 
isolations were performed on ice and all 
instruments and buffers were chilled to 4 oC before 
isolation using our established protocols (56). 
Cardiac tissue was removed and rinsed in 
mitochondrial isolation medium (MIM) containing 
300 mM sucrose, 10 mM Na-HEPES (pH=7.2) 
and 1 mM EGTA (Sigma-Aldrich, St. Louis, MO). 
The tissue was minced for 5 mins and diluted in 
MIM+BSA (1mg/ml BSA) (pH=7.4). Tissue was 
then subjected to homogenization with a Teflon 
Potter homogenizer. The homogenate was 
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centrifuged at 800 x g for 10 mins and the 
supernatant was centrifuged at 12,000 x g for 15 
mins. The mitochondrial pellet was resuspended in 
MIM and stored at -80 oC. Protein content was 
determined using a BCA protein quantification 
assay (Thermo Fisher Scientific, Waltham, MA). 
 
Electrospray ionization mass spectrometry. 
Phospholipid molecular species were determined 
in lipid extracts (0.2 mg) of mitochondrial protein 
by liquid chromatography with electrospray 
ionization mass spectrometry (LC/MS) and 
analyzed as previously described (83).  
 
Small unilamellar vesicle formation and fusion 
with mitochondria. Small unilamellar vesicles 
(SUVs) were generated using 0.025 mg of 
(18:2)4CL (Avanti Polar Lipids, Alabaster, AL) 
(84). Multilamellar vesicles (MLVs) were first 
constructed as previously shown (85). SUVs were 
then formed by the sonication of the MLVs using 
a Branson Digital Sonifier. SUVs were added to 1 
mg of total mitochondrial protein and allowed to 
gently shake for an hour at 4oC. Excess SUVs 
were then removed from the fused mitochondria 
and the mitochondrial pellet was resuspended and 
stored at -80oC. 
 
Blue-native PAGE for quantifying supercomplex 
formation. BN-PAGE was performed as 
previously described (56). Briefly, pelleted 
mitochondria were resuspended in Native PAGE 
Sample Buffer (Life Technologies, Carlsbad, CA) 
and solubilized using an 8:1 digitonin (Sigma-
Aldrich, St. Louis, MO) to protein ratio. After 
solubilization and centrifugation, the supernatants 
were collected, and protein content was 
determined via a BCA protein quantification assay 
(Thermo Fisher Scientific, Waltham, MA). 
Samples were combined with 5% G-250 sample 
additive (Life Technologies, Carlsbad, CA) and 
loaded onto the 3-12% Bis-Tris gel (Life 
Technologies, Carlsbad, CA). The gel was run on 
ice at 150 V for 3 hours. Gels were fixed using 
40% methanol and 10% acetic acid (Sigma-
Aldrich, St. Louis, MO) and destained in 8% 
acetic acid. Gels were imaged and quantified using 
the ChemiDoc Imaging System (Bio-Rad, 
Hercules, CA). Data were normalized to the total 
amount of protein in each sample. 
 
Construction of biomimetic mitochondrial giant 
unilamellar vesicles (GUVs) to quantify domain 
organization. Biomimetic mitochondrial GUVs 
were constructed by co-dissolving lipids - 39.9 
mol% 18:0-22:6 PC, 30.0 mol% 16:0-20:4 PE, 20 
mol% (18:2)4CL or (22:6)4CL, 5 mol% 18:1-18:1 
phosphatidylinositol (PI), 3 mol% 18:1-18:1 
phosphatidylserine (PS), and 2 mol% cholesterol 
(Chol), with the CL-specific fluorescent probe 
nonyl acridine orange (NAO) (0.1 mol%), in 
chloroform (0.5 mg/mL). (22:6)4CL was a custom 
synthesis from Avanti Polar Lipids. The levels of 
PC, PE, CL, PI, PS, and Chol approximated ratios 
found in the inner mitochondrial membrane. 5.0 
µg of total lipid was spread onto the conductive 
side of an indium tin oxide coated glass slide. The 
lipid-coated slide was subjected to dark vacuum 
overnight to remove excess solvent. Once the lipid 
film was dried, a GUV electroformation chamber 
was assembled as described (86). 
GUVs were constructed by 
electroformation at room temperature as 
previously described (39). To promote 
microdomain formation, cytochrome c was added 
at a 29:1 lipid to protein ratio. Following sample 
preparation, vesicles were drawn into a rectangular 
micro-capillary tube, mounted onto a microscope 
slide, and imaged at 23 oC. 
 
Confocal microscopy and image analysis. Imaging 
was conducted with an Olympus FV1000 
Confocal Microscope using a 60X 1.35NA oil 
immersion objective (Olympus, Waltham, MA). 
The NAO probe was excited with an Argon laser 
at 488 nm. All acquired images were of GUV 
equatorial cross-sections. Analysis of lipid 
domains was conducted with NIH ImageJ software 
as shown previously (39).  
 
Quantification of the Gibbs free energy of lipid 
mixing. To quantify the Gibbs free energy of lipid-
lipid mixing, biomimetic mitochondrial 
monolayers were generated by co-dissolving lipids 
(40 mol% 18:0-22:6 PC, 30.0 mol% 16:0-20:4 PE, 
20 mol% (18:2)4CL or (22:6)4CL, 5 mol% 18:1-
18:1PI, 3 mol% 18:1-18:1PS, and 2 mol% Chol) in 
chloroform (2.5 mg/mL). Lipid monolayers were 
constructed by spotting approximately 9.0 nmol on 
a subphase of 10 mM sodium phosphate buffer 
(pH 7.4). Biomimetic mitochondrial monolayers 
were analyzed in the absence and presence of 
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cytochrome c. Excess chloroform was allowed to 
evaporate for 10 min prior to cytochrome addition 
and monolayer compression. Pressure-area 
isotherms were generated and analyzed as 
previously described (39). The excess area per 
molecule and Gibbs free energy were calculated to 
quantify lipid-lipid mixing, and are presented as 
the change upon the addition of cytochrome c  
(39). All lipid mixtures were acquired multiple 
times to ensure reproducibility.    
 
Synthesis of large unilamellar vesicles (LUVs). 
LUVs were constructed at room temperature, as 
previously described (39), using the same lipid 
mixture described above for GUV and monolayer 
studies containing either (18:2)4CL or (22:6)4CL.  
 
Surface plasmon resonance (SPR). SPR data were 
recorded on an OpenSPR system (Nicoya 
Lifesciences). For all experiments, PBS (10 mM 
Na2HPO4, 2.7 mM KCl, and 137 mM NaCl, pH 
7.4) was used as the running buffer. Solubilized 
complex IV in 25 mM Tris-HCl buffer (pH 7.8), 5 
mM EDTA, and 39 mM n-dodecyl β·-D-maltoside 
(Sigma-Aldrich) was diluted to 100 µg/mL in 
activation buffer and immobilized on a gold-plated 
carboxyl-functionalized nanosensor chip 
according to manufacturer instructions using 
carbodiimide crosslink chemistry (Nicoya 
Lifesciences). After immobilization and blocking 
(10 min), LUVs  in differing concentrations were 
injected (200 µL) and allowed to interact with the 
sensor for 10 min at a pump speed of 20 µL/min. 
Complete dissociation of LUV’s from the 
immobilized complex IV was observed after 15 
min. Interactions between complex IV and the 
LUVs were determined in triplicate using three 
different chips to eliminate the possibility of chip-
to-chip variability.  Sensorgrams obtained for the 
(18:2)4CL were globally fit to a one-site binding 
model using TraceDrawer (Nicoya Lifesciences) 
to determine the association constant (kon, M-1 sec-
1), dissociation constant (koff, sec-1), and the 
equilibrium binding constant (Kd, µM). Rate 
constants were obtained from global fits using 4-5 
concentrations of LUVs and are presented as 
average ± S.D. from three separate experiments.  
 
Mitochondrial kinetic assays. Kinetic assays were 
conducted using a UV-Vis 1800 
Spectrophotometer at 37oC as previously 
demonstrated (56). Complex I activity was 
measured by monitoring the oxidation of 0.8 mM 
NADH (Sigma-Aldrich, St. Louis, MO) at 340 
nm. Complex II activity was measured by the 
reduction of 80 µM dichlorophenolindophenol 
(Sigma-Aldrich, St. Louis, MO) at 600 nm. 
Complex III activity was assayed by monitoring 
the reduction of 40 µM cytochrome c (Sigma-
Aldrich, St. Louis, MO) at 550 nm. Complex IV 
activity was measured by monitoring the oxidation 
of 10 µM reduced cytochrome c (Sigma-Aldrich, 
St. Louis, MO) at 550 nm. Complex V activity 
was measured by the oxidation of 1 mM NADH 
(Sigma-Aldrich, St. Louis, MO) at 340 nm. The 
activity of complexes I+III and II+III were 
measured by monitoring the reduction of 40 µM 
cytochrome c at 550 nm. Citrate Synthase activity 
was assayed using 0.1 mM 5,5-dithio-bis-(2-
nitobenzoic acid) (Sigma-Aldrich, St. Louis, MO).  
Each reaction was performed in duplicate and all 
activities were normalized to citrate synthase 
activity. 
 
Statistical analyses. Data are presented as average 
± S.D. All data are from multiple independent 
experiments, as indicated in the figure legends. 
Each independent experiment consisted of 1 
mouse per diet group. The human data were 
analyzed with an unpaired one-tail t-test since 
previous studies have established an increase in 
DHA levels in the myocardium (18); therefore, the 
null hypothesis for this study was set to test if 
diabetics would increase DHA levels. The mouse 
data were normally distributed based on a 
Kolmogorov-Smirnov test. Thus, these results 
were analyzed with parametric statistics using 
GraphPad Prism 7 software. Statistical 
significance was established using a one-way 
ANOVA followed by a post-hoc Bonferroni test. P 
< 0.05 was considered significant.
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Table 1. Binding constants for biomimetic mitochondrial membranes containing (18:2)4CL with complex 
IV. Large unilamellar vesicles were constructed containing either (18:2)4CL or (22:6)4CL. Vesicles were 
then used for binding studies with immobilized complex IV using surface plasmon resonance. Data are 
average ± S.D. from 3 independent experiments, n.d. indicates not detectable.    
Constant (18:2)4CL (22:6)4CL 
kon 500 ± 10 M-1 sec-1 n.d. 
koff 7.6 ± 0.2 (x10-4) sec-1 n.d. 
Kd 1.8 ± 0.6 µM n.d. 
 
Figure Legends 
Figure 1. Type 2 diabetic subjects have elevated cardiac DHA (22:6) levels relative to controls. 
Relative percentage of (A) saturated fatty acids (SFAs), (B) monounsaturated fatty acids (MUFAs), (C) n-
6 polyunsaturated fatty acids (PUFAs) and (D) n-3 PUFAs for control (CON) and type 2 diabetics (T2D). 
Values represent total fatty acids that were extracted from human tissue. Data are the average ± S.D. from 
7-8 subjects per group. Asterisks indicate significance from control (CON) (*p<0.05). 
 
Figure 2. Metabolic profile of mice consuming a Western diet in the absence or presence of EPA 
and DHA for differing time points. (A) Schematic of the diet feeding schedule for mice consuming the 
control (CON), Western diet (WD), and WD containing EPA or DHA ethyl esters. (B) Body weights at 
the end of the 14 week feeding period. (C) Fat and (D) lean mass determined by Echo-MRI. (E) Whole-
body glucose tolerance test, performed by intraperitoneal injection of glucose after a 5 hr fast. (F) Area 
under the curve (AUC), calculated by integration of the raw GTT curves shown in E. (G) Fasting insulin 
and (H) fasting glucose levels. (I) HOMA-IR scores. Data are the average ± S.D. from 8-20 independent 
experiments. Asterisks indicate significance from control (CON) (*p<0.05; **p<0.01; ***p<0.001, 
****p<0.0001). Horizontal bars with asterisks indicate significance between treatments. For simplicity, 
statistical significance is not indicated between time points (14 and 4 wks). 
 
Figure 3. Cardiac mitochondrial cardiolipin acyl chains are remodeled in response to a Western 
diet in the absence and presence of EPA and DHA. Heat maps of (A) major, (B) intermediate and (C) 
minor CL acyl chains for mice consuming a control (CON), Western diet (WD), WD+EPA, and 
WD+DHA.  (D) Monolyso-CL species in cardiac mitochondria are also shown. Data are the average from 
5 independent experiments. Asterisks indicate significance from CON (*p<0.05).  Crosses indicate 
significance relative to the WD (†p<0.05) and hash tags indicate significance between EPA and DHA at 14 or 
4 weeks (#p<0.05). For simplicity, statistical significance is not indicated between time points (14 and 4 
wks). 
 
Figure 4. Cardiac mitochondrial PC and PE acyl chains are remodeled in response to a Western 
diet in the absence and presence of EPA and DHA. Heat maps of (A) PC and (B) PE acyl chains in 
cardiac mitochondria for mice consuming a control (CON), Western diet (WD), WD+EPA, and 
WD+DHA. Data are the average from 5 independent experiments. Asterisks indicate significance from 
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CON (*p<0.05). Crosses indicate significance from WD (†p<0.05), and hash tags indicate significance 
between EPA and DHA at 14 or 4 weeks (#p<0.05). For simplicity, statistical significance is not indicated 
between time points (14 and 4 wks). 
 
Figure 5. EPA and DHA administration to a Western diet lowers select murine cardiac 
mitochondrial enzyme activities. (A) Complex I activity, measured by NADH oxidation for mice 
consuming a control (CON), Western diet (WD), WD+EPA, and WD+DHA. (B) Complex II activity, 
assessed by DCU reduction. (C) Complex III activity, assayed by cytochrome c reduction. (D) Complex 
IV activity, measured by cytochrome c oxidation. (E) Complex V activity, measured by the oxidation of 
NADH. (F) Complex I+III activity measured by NADH oxidation coupled to cytochrome c reduction. (G) 
Complex II+III activity assayed by succinate oxidation coupled to cytochrome c reduction. Activities 
were determined relative to total protein content and then normalized to citrate synthase (CS) activity. 
Data are the average ± S.D. from 5-6 independent experiments. Asterisks indicate significance from CON 
(*p<0.05, **p<0.01). Horizontal bars with asterisks indicate significance between treatments.  
 
Figure 6. Replacement of (18:2)4CL with (22:6)4CL prevents formation of lipid domains due to a 
favorable Gibbs free energy of mixing.  (A) Sample confocal images of biomimetic giant unilamellar 
vesicles containing either (18:2)4CL or (22:6)4CL. Cytochrome c (Cyt C) was added to promote phase 
separation and images were visualized with the CL-specific probe NAO. Biomimetic membranes 
modeled the composition of the inner mitochondrial membrane. (B) Frequency distribution of the 
differing areas occupied by the NAO probe on the perimeter of the vesicles. A Gaussian fit was applied to 
the data. (C) Average area occupied by the NAO fluorophore measured with NIH ImageJ software. Each 
dot represents a single GUV. Monolayers were also constructed to assay lipid-lipid miscibility. Sample 
pressure-area isotherms of biomimetic monolayers are presented containing either  (D) (18:2)4CL or (E) 
(22:6)4CL. Lipid-lipid miscibility was quantified at a physiologically relevant surface pressure of 30 
mN/m in terms of the change in (F) excess area per molecule and (G) Gibbs free energy of mixing upon 
cytochrome c addition. Negative values for excess area per molecule and Gibbs free energy indicate 
favorable lipid-lipid mixing. Positive values indicate unfavorable mixing. Data are average ± SD from 3-6 
independent experiments. Asterisks indicate statistical significance relative to (18:2)4CL: *p<0.05, 
**p<0.01. 
 
Figure 7:  Replacement of (18:2)4CL with (22:6)4CL in biomimetic mitochondrial vesicles prevents 
binding to complex IV.  Representative SPR sensorgrams of biomimetic LUVs containing (A) (18:2)4CL 
or (B) (22:6)4CL binding to complex IV. LUVs modeled the composition of the inner mitochondrial 
membrane. Solubilized complex IV was immobilized to gold-plated carboxyl sensor chips using 
EDC/NHS chemistry (Nicoya Lifesciences). Binding of varying concentrations of LUVs were measured 
as a function of time. Small increases in the signals of (22:6)4CL are attributed to non-specific binding 
interactions between the LUVs and sensor chip at high concentrations. Data in (A) were globally fit to a 
one-site binding model (solid black line, TraceDrawer) to determine kon, koff, and equilibrium dissociation 
constants. Binding constants (Table 1) were determined in three separate experiments using three 
different chips to account for chip-to-chip variability. 
 
 
Figure 8. Incorporation of (18:2)4CL improves the cardiolipin lipidome of mitochondria isolated from 
DHA fed mice. Heat maps of (A) major, (B) intermediate and (C) minor CL acyl chains for mice 
consuming a control (CON), Western diet (WD), and WD+DHA.  (D) Monolyso-CL species in cardiac 
mitochondria are also shown. Data are the average ± S.E.M. from 3 independent experiments. Asterisks 
indicate significance from CON (*p<0.05). Crosses indicate significance relative to 
WD+DHA+(18:2)4CL (†p<0.05). 
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Figure 9. (18:2)4CL rescues the DHA-induced loss of complex I, IV, and V activities.  (A) Complex I 
activity, measured by NADH oxidation for mice consuming a control (CON), Western diet (WD) and 
WD+DHA. (B) Complex II activity, measured by DCU reduction. (C) Complex III activity, assayed by 
cytochrome c reduction. (D) Complex IV activity, measured by cytochrome c oxidation. (E) Complex V 
activity, measured by the oxidation of NADH. (F) Complex I+III activity assayed by NADH oxidation 
coupled to cytochrome c reduction. (G) Complex II+III activity, assessed by succinate oxidation coupled 
to cytochrome c reduction. Activities were determined relative to total protein content and then 
normalized to citrate synthase (CS) activity. Data are the average ± S.E.M. from 4 independent 
experiments. Asterisks indicate significance from CON (*p<0.05, **p<0.01) . Horizontal bars with 
asterisks indicate significance between treatments. 
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